EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) Annals of the Rheumatic Diseases Gout Gouty Arthritis In Depth: Risk Factors, Treatment What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or